Study of SIBP-A16 for preterm and full-term infants at risk of RSV
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This trial tests a new medicine called SIBP-A16 to help protect infants from RSV, a common virus that can cause serious breathing problems. It is for preterm and full-term infants under 1 year old who are entering their first RSV season.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Infant is under 1 year old, including both preterm and full-term babies.
- Baby weighs at least 3 kg (about 6.6 pounds) at the start of the study.
- Baby is entering their first RSV season (when RSV is most common).
- Parent or legal guardian agrees to follow the study plan, attend visits, and give blood samples.
- Baby must not have had a fever or acute illness in the last 7 days, or an RSV infection before the study starts.
- Baby cannot have certain health problems, like serious lung or heart conditions, or a history of severe allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
This study tests whether giving a special antibody medicine (called RSV-SMA) to babies aged 6–9 months can help prevent respiratory syncytial virus (RSV), a common virus that causes serious breathing problems in young children. Your baby would receive the medicine and be followed to see if it helps protect them.
This study tests a medication called palivizumab to help protect certain children from severe RSV (a common respiratory virus). It is for infants and young children with a higher chance of getting very sick from RSV, such as premature babies or those with certain heart or lung conditions.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This study watches infants in Brazil who are hospitalized or visit a clinic with breathing problems to see if their mother's RSV vaccine helped protect them. It may help doctors understand how well the vaccine works in real life.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.